#384 - Special episode - Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention - The Peter Attia Drive Recap

Podcast: The Peter Attia Drive

Published: 2026-03-16

Duration: 53 min

Summary

Peter Attia explores the potential of Obicetrapib, a CETP inhibitor, in reducing cardiovascular risks and possibly preventing Alzheimer's disease, particularly in APOE4 carriers.

What Happened

Peter Attia delves into Obicetrapib, a CETP inhibitor that has generated significant excitement in cardiovascular medicine due to its potential to lower LDL cholesterol and APOB levels. He explains the drug's mechanism and its history, noting the failures of previous CETP inhibitors due to off-target toxicity or insufficient LDL reduction. Obicetrapib, however, showed promising results in Phase II trials, with substantial reductions in LDL cholesterol even when added to high-intensity statin therapy.

The Broadway study, a Phase III trial, focused on patients with atherosclerotic disease or familial hypercholesterolemia who were already on maximum lipid-lowering therapy. Obicetrapib demonstrated a 30% additional reduction in LDL cholesterol and a 16% reduction in APOB. Interestingly, it also reduced LP-little A by a third, a difficult-to-modify cardiovascular risk factor, suggesting a potential mechanism involving decreased synthesis of apolipoprotein little A.

Attia discusses the broader implications of CETP inhibitors like Obicetrapib on brain health, particularly for Alzheimer's disease. He highlights the potential for these drugs to improve lipid trafficking in the brain, especially in APOE4 carriers, who are at increased risk for Alzheimer's due to impaired cholesterol transport. The Broadway study's biomarker analysis showed a significant attenuation in PTAU217 progression, with the most pronounced effects in APOE4E4 individuals.

While the study is promising, Attia cautions that it is primarily a biomarker study, not a cognitive outcomes trial. He emphasizes the need for more data, particularly long-term studies that include cognitive outcomes and larger genomic stratified groups. Despite the challenges, Attia expresses optimism about the potential of Obicetrapib to address both cardiovascular and neurological health.

Attia underscores the importance of understanding the history and biology of CETP inhibitors, noting that the failures of previous drugs have informed the development of Obicetrapib. He stresses the need for cautious optimism, given that the observed biomarker changes in the Broadway study may not directly translate to clinical benefits without further research.

The episode also touches on the approval process, noting that while Europe has approved the drug based on biomarkers, the U.S. will require hard outcomes like mortality benefits or major adverse cardiac event reductions. Attia speculates that the drug could be available in Europe by the end of 2026, but U.S. approval will likely take longer.

Key Insights

• Obicetrapib, a CETP inhibitor, achieved a 30% additional reduction in LDL cholesterol and a 16% reduction in APOB in patients already on maximum lipid-lowering therapy during the Broadway Phase III trial.
• The Broadway study found that Obicetrapib reduced LP-little A levels by a third, suggesting a potential mechanism involving decreased synthesis of apolipoprotein little A, a challenging cardiovascular risk factor to modify.
• Biomarker analysis from the Broadway study indicated a significant attenuation in PTAU217 progression in APOE4E4 individuals, hinting at potential benefits for Alzheimer's disease, although cognitive outcomes were not directly assessed.
• While Europe may approve Obicetrapib based on biomarker results by the end of 2026, U.S. approval is expected to take longer as it requires evidence of mortality benefits or reductions in major adverse cardiac events.